Emmessar Biotech & Nutrition Past Earnings Performance
Past criteria checks 4/6
Emmessar Biotech & Nutrition's earnings have been declining at an average annual rate of -8.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 4.3% per year. Emmessar Biotech & Nutrition's return on equity is 8.3%, and it has net margins of 23.2%.
Key information
-8.5%
Earnings growth rate
-8.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -4.3% |
| Return on equity | 8.3% |
| Net Margin | 23.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Emmessar Biotech & Nutrition makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 25 | 6 | 10 | 0 |
| 30 Sep 23 | 25 | 4 | 9 | 0 |
| 30 Jun 23 | 26 | 4 | 9 | 0 |
| 31 Mar 23 | 25 | 5 | 9 | 0 |
| 31 Dec 22 | 29 | 3 | 8 | 0 |
| 30 Sep 22 | 21 | 5 | 8 | 0 |
| 30 Jun 22 | 25 | 6 | 8 | 0 |
| 31 Mar 22 | 18 | 5 | 8 | 0 |
| 31 Dec 21 | 62 | 10 | 8 | 0 |
| 30 Sep 21 | 73 | 12 | 8 | 0 |
| 30 Jun 21 | 84 | 15 | 7 | 0 |
| 31 Mar 21 | 85 | 14 | 6 | 0 |
| 31 Dec 20 | 47 | 9 | 6 | 0 |
| 30 Sep 20 | 40 | 7 | 6 | 0 |
| 30 Jun 20 | 30 | 4 | 6 | 0 |
| 31 Mar 20 | 48 | 8 | 6 | 0 |
| 31 Dec 19 | 41 | 9 | 6 | 0 |
| 30 Sep 19 | 37 | 9 | 6 | 0 |
| 30 Jun 19 | 37 | 8 | 7 | 0 |
| 31 Mar 19 | 19 | 5 | 6 | 0 |
| 31 Dec 18 | 18 | 6 | 6 | 0 |
| 30 Sep 18 | 16 | 7 | 5 | 0 |
| 30 Jun 18 | 21 | 9 | 4 | 0 |
| 31 Mar 18 | 25 | 9 | 4 | 0 |
| 31 Dec 17 | 29 | 10 | 5 | 0 |
| 30 Sep 17 | 29 | 12 | 4 | 0 |
| 30 Jun 17 | 21 | 10 | 4 | 0 |
| 31 Mar 17 | 36 | 12 | 4 | 0 |
| 31 Dec 16 | 24 | 2 | 4 | 0 |
| 30 Sep 16 | 18 | -2 | 4 | 0 |
| 30 Jun 16 | 19 | -3 | 4 | 0 |
| 31 Mar 16 | 20 | -5 | 3 | 0 |
| 31 Dec 15 | 16 | 2 | 5 | 0 |
| 30 Sep 15 | 29 | 2 | 6 | 0 |
| 30 Jun 15 | 31 | 2 | 5 | 0 |
| 31 Mar 15 | 22 | -1 | 3 | 0 |
| 31 Dec 14 | 27 | -4 | 6 | 0 |
| 30 Sep 14 | 14 | -4 | 6 | 0 |
| 30 Jun 14 | 10 | -5 | 2 | 0 |
| 31 Mar 14 | 15 | -3 | 4 | 0 |
| 31 Dec 13 | 10 | -2 | 4 | 0 |
| 30 Sep 13 | 11 | -2 | 4 | 0 |
| 30 Jun 13 | 10 | -1 | 2 | 0 |
Quality Earnings: 524768 has high quality earnings.
Growing Profit Margin: 524768's current net profit margins (23.2%) are higher than last year (11.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524768's earnings have declined by 8.5% per year over the past 5 years.
Accelerating Growth: 524768's earnings growth over the past year (68.3%) exceeds its 5-year average (-8.5% per year).
Earnings vs Industry: 524768 earnings growth over the past year (68.3%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 524768's Return on Equity (8.3%) is considered low.